Pearl Steinzor

Most specialty pharmacist interventions were routine refill and adherence touchpoints, with symptom trends driving higher-stakes provider escalations.

Tiara Green of Accessia Health says demand for charitable patient assistance is outpacing donations as inflation and Part D changes strain patients.

Nearly 3 in 4 bariatric surgery candidates had clinical obesity, a phenotype that BMI alone did not distinguish from preclinical obesity.

A meta-analysis of 27 trials found a 15% cardiovascular risk reduction per 10-mm Hg lower systolic BP, with no added risk of kidney failure.

In a Japanese registry of 1235 patients with AMI treated with PCI, Lp(a) of 24 mg/dL or higher independently predicted MACE and HF hospitalization.

Experts highlight AI adoption, sustained-release glaucoma therapies, and concerns about Medicare payment and rural access.

A meta-analysis of HELIOS-B and CARDIO-TTRansform found gene silencers reduced death and CV events, driven by patients not taking stabilizers.

ApoB more directly reflects atherogenic particle burden than LDL-C, but missing outcome trials and assay variability still limit its routine use.

In states that covered obesity-labeled GLP-1 RAs, total GLP-1 RA use rose less than obesity-labeled use alone, suggesting possible substitution.

SURPASS-CVOT data show fewer deaths or HF events with tirzepatide vs dulaglutide in patients with HF, driven largely by mortality.

The Franklin County death is under state review as Pennsylvania's measles outbreak passed 1100 cases and 219 hospitalizations.

The expanded indication rests on evidence extrapolated from carcinoma in situ, a new FDA approach to closely related forms of bladder cancer.

AI tools are streamlining retina practice, but adoption depends on fitting them into real-world workflows.

Cataract surgery improved vision across all AMD stages, but patients with advanced dry AMD lost their gains by about 30 months.

New 12-month phase 1/2 data show the BIM-IOL System lowered IOP and kept most patients drop-free after cataract surgery.

In the pivotal BRUNELLO trial, both doses of remigromig, a Wnt pathway agonist, were noninferior to ranibizumab for diabetic macular edema at 1 year.

Access to emergency eye care remains a public health challenge, with gaps that affect patients and communities across the country.

Cost, staffing, unbiased training data, and strong referral partnerships will decide whether AI eye screening reaches patients at highest risk of vision loss.

The director of the National Eye Institute discusses recent advances, AI, and evolving standards of care in ophthalmology.

Two inSPire2026 posters detail how health system specialty pharmacy teams support patients with ATTR-CM.

Population growth and aging, not rising age-standardized rates, drives the increase, with underlying causes varying widely by age and region.

A JAMA analysis of 2021-2023 death records found heat-related mortality varied sharply by occupation and industry among working-age US adults.

A legal fight over a single amino acid could set retatrutide's exclusivity window, its Medicare negotiation clock, and its competitive future.

Stutsky explains why shifting therapy perceptions had more pharmacist touchpoints and longer time on therapy among patients with ATTR-CM.

Moderate coffee intake may lower cardiovascular risk, but energy drinks may harm the heart.

The approval is based on findings from the phase 3 SCOUT-HCM trial.

Average stand-alone Part D premiums are projected to rise by less than $1 a month as a temporary subsidy program ends after 2026.

Pharmacy leaders examined AI for authorizations, adherence, patient access, and efficient specialty pharmacy benefits in health-system care.

The triple agonist also lowered HbA1C by up to 1.6% over 80 weeks, with up to 40% of participants reaching normal levels.

Symptom-tracking tools may improve awareness and patient-clinician communication but can also add stress.